Trade BNTX

BioNTech SE

-

00:00:00

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Read more...

1D Change

2.910%

Why BlackBull Markets?

26k+

Tradable Assets

1:500

Leverage up to

Regulated

Multi-Regulated

24/7

Customer Support

$0

No Minimum Deposit

TRADING CONDITIONS

BNTX
TRADING CONDITIONS

Digits

3

Point

0.001

Spread

 
floating

Contract Size

1

Volume Min

1

Volume Max

10,000

Volume Step

1

Swap Long (Points)

 
-33.320

Swap Short (Points)

-19.280
Available on
MT5, TV, cTrader
Last update at June 14, 20:08 GMT+3
*Data Source: MT5 Server Prime Account Pricing

Margin Calculator

Calculation Results

Current Price

91.98

Required Margin

Converted Currency

Required Margin

Account Base Currency

How it works:

Use our margin calculator to determine the funds required to open and maintain positions.

Select your account base currency, an asset pair, the size of your position in lots, and your level of leverage. 


The calculation is carried out as follows:
Required Margin = Trade Size / Leverage * Account Currency Exchange Rate

Profit/Loss Calculator

Calculation Results

PIP Value:

Stop loss in PIPs

Stop loss at :

Take profit in PIPs

Take profit at :

How it works:

Use our profit and loss calculator to determine where to place your take profit and stop loss. 

 

Select your account base currency, an asset pair, the size of your position in lots, choose between a long buy and a short sell, and input a stop loss and take profit value. 


The calculation is carried out as follows:
SL / TP Levels = SL, TP Amount / Pip Value Formula * Exchange Rate

Swaps Calculator

Calculation Results

91.98

How it works:

Use our swaps calculator to determine the interest rate differential between two assets. 

 

Select your account base currency, an asset pair, the size of your position in lots. 


The calculation is carried out as follows:
Swap = (One Point / Exchange Rate) * Trade Size (Lot Size) * Swap Value in Points

Currency Calculator

Calculation Results

Loading...

How it works:

Use our currency calculator to determine the value of one currency against another, based on current exchange rates.

Join Now